Cargando…

A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer

BACKGROUND: PHI-101 is an orally available, selective checkpoint kinase 2 (Chk2) inhibitor. PHI-101 has shown anti-tumour activity in ovarian cancer cell lines and impaired DNA repair pathways in preclinical experiments. Furthermore, the in vivo study suggests the synergistic effect of PHI-101 throu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Soo Jin, Chang, Suk-Joon, Suh, Dong Hoon, Kong, Tae Wook, Song, Heekyoung, Kim, Tae Hun, Kim, Jae-Weon, Kim, Hee Seung, Lee, Sung-Jong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722005/ https://www.ncbi.nlm.nih.gov/pubmed/34980026 http://dx.doi.org/10.1186/s12885-021-09138-z

Ejemplares similares

Position statements on genetic test for peritoneal, ovarian, and fallopian tubal cancers: Korean Society of Gynecologic Oncology (KSGO)
por: Choi, Min Chul, et al.
Publicado: (2016)

Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer
por: Indini, Alice, et al.
Publicado: (2021)

Significance of cholecystectomy in cytoreductive surgery for advanced ovarian cancer
por: Son, Joo-Hyuk, et al.
Publicado: (2023)

Cost–utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea: results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model
por: Lee, Hwa-Young, et al.
Publicado: (2013)

Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
por: Hwangbo, Suhyun, et al.
Publicado: (2021)

Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles
por: Kim, Se Ik, et al.
Publicado: (2020)

Improvements to the FIGO staging for ovarian cancer: reconsideration of lymphatic spread and intraoperative tumor rupture
por: Suh, Dong Hoon, et al.
Publicado: (2013)

Metformin against Cancer Stem Cells through the Modulation of Energy Metabolism: Special Considerations on Ovarian Cancer
por: Kim, Tae Hun, et al.
Publicado: (2014)

RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma
por: Kim, Kyeongmin, et al.
Publicado: (2023)

A Mathematical Model for Predicting Patient Responses to Combined Radiotherapy with CTLA-4 Immune Checkpoint Inhibitors
por: Kim, Yongjin, et al.
Publicado: (2023)

Simplified Selection Criteria for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer
por: Son, Joo-Hyuk, et al.
Publicado: (2022)

Impact of Underweight after Treatment on Prognosis of Advanced-Stage Ovarian Cancer
por: Kim, Se Ik, et al.
Publicado: (2014)

Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial
por: Lee, Jung-Yun, et al.
Publicado: (2022)

Induction of Ia Antigens on Synovial Cells by Gamma Interferon
por: Kim, Seong-Yoon, et al.
Publicado: (1987)

Clinicopathologic characteristics of ovarian clear cell carcinoma in the background of endometrioma: a surveillance strategy for an early detection of malignant transformation in patients with asymptomatic endometrioma
por: Son, Joo-Hyuk, et al.
Publicado: (2019)

Management of ovarian cancer patients in affected areas during COVID-19 pandemic: Japan and Korea
por: Kobayashi, Yusuke, et al.
Publicado: (2020)

Gastrointestinal/genitourinary perforation and fistula formation with or without bevacizumab in patients with previously irradiated recurrent cervical cancer: a Korean multicenter retrospective study of the Gynecologic Oncology Research Investigators Collaboration (GORILLA) group (GORILLA-1001)
por: Hwang, Woo Yeon, et al.
Publicado: (2022)

Platinum on 2-aminoethanethiol functionalized MIL-101 as a catalyst for alkene hydrosilylation
por: Xie, Zhikai, et al.
Publicado: (2019)

An Ovarian Steroid Cell Tumor Causing Virilization and Massive Ascites
por: Kim, Young Tae, et al.
Publicado: (2007)

Effect of BRCA1/2 Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study
por: Kim, Se Ik, et al.
Publicado: (2023)

SERPINB3 in the Chicken Model of Ovarian Cancer: A Prognostic Factor for Platinum Resistance and Survival in Patients with Epithelial Ovarian Cancer
por: Lim, Whasun, et al.
Publicado: (2012)

Risk factors for the failure of first‐line PARP inhibitor maintenance therapy in patients with advanced ovarian cancer: Gynecologic Oncology Research Investigators Collaboration Study (GORILLA‐3004)
por: Kim, Nam Kyeong, et al.
Publicado: (2023)

Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer
por: Luo, Yanlin, et al.
Publicado: (2016)

Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer
por: Paik, E Sun, et al.
Publicado: (2017)

Gynecologic cancer clinical practice guidelines in Korea and current issues
por: Kim, Jeeyeon, et al.
Publicado: (2022)

The BRCA2 p.N372 H i.a.1342A>C Could Regulate the Sensitivity of Ovarian Cancer Cells to Platinum-Based Drugs
por: Du, Zhen-Hua, et al.
Publicado: (2020)

High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer
por: Han, Gwan Hee, et al.
Publicado: (2023)

The 34th Annual Meeting of the Korean Society of Gynecologic Oncology 2019: meeting report
por: Yim, Ga Won, et al.
Publicado: (2019)

Stratifying the risk of ovarian cancer incidence by histologic subtypes in the Korean Epithelial Ovarian Cancer Study (Ko‐EVE)
por: Sung, Soseul, et al.
Publicado: (2023)

Correction: SERPINB3 in the Chicken Model of Ovarian Cancer: A Prognostic Factor for Platinum Resistance and Survival in Patients with Epithelial Ovarian Cancer
por: Lim, Whasun, et al.
Publicado: (2013)

Clinical Significance of Microsatellite Instability in Sporadic Epithelial Ovarian Tumors
por: Yoon, Bo-Sung, et al.
Publicado: (2008)

The prognosis of stage IA synchronous endometrial endometrioid and ovarian carcinomas
por: Zhan, Xiangbo, et al.
Publicado: (2019)

Phenolic Hydroxyl Groups in the Lignin Polymer Affect the Formation of Lignin Nanoparticles
por: Lee, Jae Hoon, et al.
Publicado: (2021)

Expression of Aspergillus nidulans phy Gene in Nicotiana benthamiana Produces Active Phytase with Broad Specificities
por: Oh, Tae-Kyun, et al.
Publicado: (2014)

Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4
por: Kim, Yoo-Na, et al.
Publicado: (2023)

Anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma in Korea: three case reports
por: Lee, Jisun, et al.
Publicado: (2021)

Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer
por: Leary, Alexandra, et al.
Publicado: (2018)

Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999–2015
por: Lim, Myong Cheol, et al.
Publicado: (2018)

3IA Conference (3IA’2011)
por: Plemenos, Dimitri, et al.
Publicado: (2012)

Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Hong, Joohyun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_onq62717uhea53t3nvo1dgvl96